



Editor Note

Marc R Matrana*

Clinical Cancer Research, Ochsner Cancer Institute, USA

***Corresponding author:** Marc R Matrana, Associate Director of Clinical Cancer Research, Ochsner Cancer Institute, USA, Tel: 504-842-3910; E-mail: mamatrana@ochsner.org

Received date: Aug 01, 2016; **Accepted date:** Aug 03, 2016; **Published date:** Aug 10, 2016

Copyright: © 2016 Matrana MR. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Matrana MR (2016) Editor Note. Med Sur Urol 5: e114. doi:[10.4172/2168-9857.1000e114](https://doi.org/10.4172/2168-9857.1000e114)

Editorial

Like all fields of medicine, medical and surgical urology is a specialty on the move. Knowledge about the underlying biology of disease—often down to the very molecules that drive life itself—is propelling the development of new drugs and new techniques, and giving new hope to patients world-wide. Many patients with metastatic bladder cancer and poor kidney function, for example, had very few systemic treatment options at the beginning of 2016, but are now benefiting greatly from novel breakthroughs in newly approved immunotherapy just a few months later. At no other time in human history has medicine ever progressed faster, knowledge been created more efficiently, or understanding been applied more appropriately to benefit so many. The Journal of Medical and Surgical Urology finds

itself among new publications leading such efforts. By disseminating new information faster and breaking down barriers across continents to share clinical observations with physicians around the globe, our journal provides a service whose impact can never be fully measured, but is no doubt influencing patient care and research efforts far and wide. We are now embarking upon the publication of the journal's fifth volume. Which each subsequent issue, I have watched the journal become sharper and more relevant. There is no doubt much more work to do, but as we continue to refine and build this journal, we will keep our goal on target—to communicate knowledge to providers across borders and beyond the limits of traditional publishing platforms to ultimately impact patients on a wide scale.